您好,欢迎光临世界标品! 登录 注册(订药物标准品请用邮件联系我们)

中国医药研发对照标品提供商
Non-clinical Research-used
Medicine Sample Provider

当前本网站药物产品种数共 8420 处方药 8047 非处方药 267 保健品/医疗用具 106

世界标品医药目录搜索(中英文):
世界各国官方药品目录搜索(英文):
世界标品医药知识搜索(中英文):

联系方式
国内客服电话:
国际免费电话:


QQ客服1:1793093587
QQ客服2:1586083059
QQ客服3:2786706041
QQ客服6:2992753224
QQ客服7:2394834588

咨询邮箱:
scimed.shanghai@shijiebiaopin.com
info@shijiebiaopin.com
pharmacy.shijiebiaopin1@gmail.com
pharmacy.shijiebiaopin2@gmail.com

  药店国别: 香港药房
产地国家: 香港
所属类别: 泌尿生殖系统及泌乳药物->促排卵
处方药:处方药
包装规格: 150微克/0.5毫升/瓶
计价单位:
  点击放大  
生产厂家中文参考译名:
默克
生产厂家英文名:
Merck
该药品相关信息网址1:
http://www.elonva.no/HCP/index.asp
该药品相关信息网址2:
http://www.news-medical.net/drugs/Elonva.aspx
该药品相关信息网址3:
http://www.virtualmedicalcentre.com/drugs.asp?drugid=3314&title=elonva-solution-for-injection
原产地英文商品名:
ELONVA SOLUTION INJECTION 150mcg 0.5ml
原产地英文药品名:
CORIFOLLITROPIN ALFA
中文参考商品译名:
ELONVA注射用溶液剂 150微克/0.5毫升/瓶
中文参考药品译名:
CORIFOLLITROPIN ALFA
原产地国家批准上市年份:
0000/00/00
英文适应病症1:
Ovulation
临床试验期:
完成
中文适应病症参考翻译1:
促排卵
药品信息:

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201221617453317.PDF,201221617420613.PDF,201221617415736.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文Elonva处方资料(仅供参考)

默沙东促排卵药Elonva已通过欧盟批准
    默沙东促排卵药Elonva(corifollitropin alfa注射剂)已通过欧盟批准,该药与GnRH拮抗剂联用对患者进行控制性促排卵(COS)。它主要用于那些采用辅助生殖技术(ART)生育的妇女,促进其卵泡发育。随着Elonva在欧盟地区获准,默克将可以在所有欧盟成员国推出这种产品,并采用统一标签。

  Elonva可持续一周促进患者多个卵泡发育。默克表示,在COS治疗周期之初,若采用常规重组卵泡刺激素(rFSH)治疗,在头7天需每天注射一次药物,而仅注射1剂Elonva就可以达到7剂rFSH的效果。

  Elonva的III期临床实验当中,有一项名为Engage的实验是迄今为止规模最大的针对治疗不孕症的试管婴儿临床实验项目。实验结果显示,Elonva受试组当中,患者在每一个治疗周期的受孕几率(实验主要终点)可达到38.9%,与使用rFSH的对照组效果相当,后者每一治疗周期受孕率为38.1%。

  默克研发实验室负责人米杰姆·莫尔·艾特斯表示:“Elonva在欧盟地区获准上市后,当地的不孕症妇女将可免去频繁注射促排卵药的困扰。默克将会再接再厉,致力于研发以患者为本的不孕症治疗药。”

Merck Receives European Approval for ELONVA? (corifollitropin alfa injection)
Merck & Co., Inc., which operates outside the U.S. and Canada as MSD, today announced the European Commission (EC) approval of ELONVA? (corifollitropin alfa injection). ELONVA is indicated for controlled ovarian stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (ART) program. With the EC approval, Merck receives marketing authorization for ELONVA with unified labeling valid in all European Union Member States. Schering-Plough Corp. and Merck & Co., Inc. merged on Nov. 3, 2009.

ELONVA is the first sustained follicle stimulant. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of ELONVA may replace the first seven injections of any conventional daily recombinant follicle stimulating hormone (rFSH) preparation in a COS treatment cycle.

"The European approval of ELONVA is a positive step towards reducing the burden of injections for women experiencing difficulty conceiving," said Mirjam Mol-Arts, senior vice president, Merck Research Laboratories. "Merck is proud of the company's women's health portfolio and is committed to providing effective patient-focused fertility treatments."

The Phase III development program for ELONVA included the Engage trial, the largest double-blind fertility agent trial in IVF performed to date. In the Engage trial, the ongoing pregnancy rate, the primary endpoint, obtained in the ELONVA treatment arm (38.9 percent per started cycle) was similar to that achieved in patients receiving a daily dose of rFSH (38.1 percent per started cycle).(1)

The most frequently reported adverse drug reactions during treatment with ELONVA in clinical trials are Ovarian Hyperstimulation Syndrome (OHSS) (5.2%), pelvic pain (4.1%) and discomfort (5.5%), headache (3.2%), nausea (1.7%), fatigue (1.4%) and breast complaints (including tenderness) (1.2%). Use with GnRH agonists is not recommended.

About ELONVA
ELONVA is approved for COS in combination with a GnRH antagonist for the development of multiple follicles in women participating in an ART program. ELONVA is designed as a sustained follicle stimulant with the same pharmacodynamic profile as rFSH, but with a markedly prolonged duration of FSH activity. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of ELONVA may replace the first seven injections of any daily rFSH preparation in a COS treatment cycle.

About Engage
Engage was a non-inferiority trial designed to compare ELONVA 150 mcg to 200 IU rFSH. A total of 1,506 patients (with a body weight greater than 60 kg) at 34 in-vitro fertilization (IVF) clinics in North America and Europe were randomized to start stimulation with either ELONVA 150 mcg or a daily dose of 200 IU rFSH for seven days. Patients also received rFSH (maximum 200 IU/day) from stimulation day eight onward, when required. Starting on stimulation day five, all patients received 0.25mg gonadotropin-releasing hormone (GnRH) antagonist until triggering of final oocyte maturation by human chorionic gonadotropin (hCG). The primary endpoint was the ongoing pregnancy rate assessed at ten weeks or more after embryo transfer. In the ELONVA treatment arm the ongoing pregnancy rate (38.9 percent per started cycle) was similar to that achieved in patients receiving a daily dose of rFSH (38.1 percent per started cycle).(1) The number of oocytes retrieved per attempt, the co-primary endpoint, was 13.7 (± 8.2) for the ELONVA group and 12.5 (± 6.7) for the rFSH group.(1)

About Infertility
Infertility is a disease or condition that impairs the body's ability to perform the basic function of reproduction.(2) It is often diagnosed after a couple has not conceived after one year of unprotected, well-timed intercourse.(3) Women over the age of 35 are encouraged to seek diagnosis and treatment for infertility following six months of unprotected intercourse.(4) Around 15 percent of couples of reproductive age have a fertility problem.(3)

There are many causes of infertility including problems with the production of sperm or eggs, with the fallopian tubes or the uterus, endometriosis, frequent miscarriage, as well as hormonal and autoimmune (antibody) disorders in both men and women.(3)

With infertile couples, the source of infertility lies with the male in 40 percent of cases and 40 percent with the female. The remaining 20 percent is either a joint problem or unknown, because the cause has not been identified. There are a variety of treatments available for infertility; these include surgery, hormone treatments, insemination and IVF, among others.(3)

About Merck
Today's Merck is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them. Merck. Be Well. For more information, visit www.merck.com.

---------------------------------------------------------------
 详细处方信息以本药内容附件PDF文件(201221617453317.PDF,201221617420613.PDF,201221617415736.PDF)的“原文Priscribing Information”为准
---------------------------------------------------------------

更新日期: 2014-09-11
附件:




201221617453317.PDF    

201221617420613.PDF    

201221617415736.PDF    

 
调控比例: 100%
订购表单下载
Copyrights © 2010,2011,2012 www.ShiJieBiaoPin.com, Inc., All rights Reserved www.ShiJieBiaoPin.com, Inc.
客服工作时间:太平洋时间18:00-24:00
国内客服电话:     国际免费电话:
友情提示:以上电话为免费电话,无需您承担任何费用,世界标品提供中文客服,请您放心拨打!
电子邮箱:info.shijiebiaopin.com@gmail.com, info@shijiebiaopin.com